Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Dynavax Stock Is Jumping Today

By Keith Speights - Dec 11, 2020 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's hepatitis B vaccine received good news in Europe.

What happened

Shares of Dynavax Technologies ( DVAX 2.20% ) are jumping today, up 7.5% as of 11:23 a.m. EST, after the company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for hepatitis B vaccine Heplisav-B.

So what

CHMP's positive recommendation is great news for Dynavax because it bodes well for the company's prospects of winning European approval for Heplisav-B. The hepatitis B vaccine has been on the market in the U.S. since 2017. 

Senior adult receiving a vaccine shot

Image source: Getty Images.

So far this year, Heplisav-B has generated U.S. sales of more than $26 million. The European Union's population is roughly 35% bigger than the U.S. population. Should Heplisav-B go on to win EU approval, Dynavax's potential market will increase dramatically.

Vaccination for hepatitis B is also arguably more critical than ever before. More than 250 million people have been infected by hepatitis B globally, with transmission of the virus increasing. It is at least 50 times more infectious than HIV. 

Now what

While Dynavax's shares enjoyed a big pop today, the momentum for the biotech stock might not be over. The European Commission is now set to review the CHMP recommendation for Heplisav-B. A decision on approval for the vaccine is expected in the first quarter of 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$13.46 (2.20%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.